A recent study demonstrated that multigene signatures constitute a reliable tool to identify T-cell pro-inflammatory phenotypes across different solid tumors, including NSCLC, likely to respond to PD-(L)1 inhibition therapy outperforming PD-L1 immunohistochemistry in PD-L1 unselected patients [94]. Here, CD274 is linked to non-small cell lung carcinoma.